The 36-month beta value for VRTX is also noteworthy at 0.42. There are mixed opinions on the stock, with 14 analysts rating it as a “buy,” 4 rating it as “overweight,” 14 rating it as “hold,” and 1 rating it as “sell.”
The public float for VRTX is 256.00M, and at present, short sellers hold a 1.58% of that float. The average trading volume of VRTX on June 27, 2025 was 1.70M shares.
VRTX) stock’s latest price update
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX)’s stock price has plunge by -0.54relation to previous closing price of 445.82. Nevertheless, the company has seen a -1.12% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-23 that VANCOUVER, British Columbia, June 23, 2025 (GLOBE NEWSWIRE) — Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) announces that it has appointed Independent Trading Group, Inc. (Address: 420, 33 Yonge Street, Toronto, ON, Canada, M5E 1G4; Website: www.itg84.com; Contact: Chris Kaplan; Email: [email protected]) (“ITG”) as a market maker for its common shares traded on the Canadian Securities Exchange (the “CSE”).
VRTX’s Market Performance
VRTX’s stock has fallen by -1.12% in the past week, with a monthly drop of -0.58% and a quarterly drop of -11.37%. The volatility ratio for the week is 2.03% while the volatility levels for the last 30 days are 2.04% for Vertex Pharmaceuticals, Inc The simple moving average for the last 20 days is -0.94% for VRTX stock, with a simple moving average of -4.50% for the last 200 days.
Analysts’ Opinion of VRTX
Leerink Partners, on the other hand, stated in their research note that they expect to see VRTX reach a price target of $503. The rating they have provided for VRTX stocks is “Market Perform” according to the report published on May 06th, 2025.
Cantor Fitzgerald gave a rating of “Overweight” to VRTX, setting the target price at $535 in the report published on April 22nd of the current year.
VRTX Trading at -3.07% from the 50-Day Moving Average
After a stumble in the market that brought VRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.71% of loss for the given period.
Stock Fundamentals for VRTX
Current profitability levels for the company are sitting at:
- -0.07 for the present operating margin
- 0.86 for the gross margin
The net margin for Vertex Pharmaceuticals, Inc stands at -0.09. The total capital return value is set at -0.04. Equity return is now at value -5.64, with -4.23 for asset returns.
Based on Vertex Pharmaceuticals, Inc (VRTX), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -0.59. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is -32.0.
Currently, EBITDA for the company is 486.3 million with net debt to EBITDA at 39.65. When we switch over and look at the enterprise to sales, we see a ratio of 9.99. The receivables turnover for the company is 6.15for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.65.
Conclusion
In summary, Vertex Pharmaceuticals, Inc (VRTX) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
